Post-IPO Equity - Aadi Bioscience
Investment Firm
Overview
Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Announced Date
Sep 22, 2022
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Investor Lead
N/A
Participant Investors
2
| Investor Name |
|---|
Round Details and Background
Aadi Bioscience raised $72500000 on 2022-09-22 in Post-IPO Equity
Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 26, 2021 |  Post-IPO Equity - Aadi Bioscience | 12 | - | 155.0M |
| Sep 22, 2022 | Post-IPO Equity - Aadi Bioscience | 5 | - | 72.5M |
| May 08, 2017 | Series A - Aadi Bioscience | 6 | - | 23.0M |
Recent Activity
There is no recent news or activity for this profile.